Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study
Background Identification of positive biomarkers for the effects of nivolumab on patients with advanced gastric cancer (AGC) is significant. The Gustave Roussy Immune Score (GRIm-s) is associated with therapeutic resistance of immune checkpoint inhibitors (ICIs) in other cancers. This multicenter, r...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2022-11, Vol.29 (12), p.7400-7406 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7406 |
|---|---|
| container_issue | 12 |
| container_start_page | 7400 |
| container_title | Annals of surgical oncology |
| container_volume | 29 |
| creator | Nakazawa, Nobuhiro Sohda, Makoto Ubukata, Yasunari Kuriyama, Kengo Kimura, Akiharu Kogure, Norimichi Hosaka, Hisashi Naganuma, Atsushi Sekiguchi, Masanori Saito, Kana Ogata, Kyoichi Sano, Akihiko Sakai, Makoto Ogawa, Hiroomi Shirabe, Ken Saeki, Hiroshi |
| description | Background
Identification of positive biomarkers for the effects of nivolumab on patients with advanced gastric cancer (AGC) is significant. The Gustave Roussy Immune Score (GRIm-s) is associated with therapeutic resistance of immune checkpoint inhibitors (ICIs) in other cancers. This multicenter, retrospective study was designed to analyze the association of GRIm-s with therapeutic sensitivity of nivolumab in patients with AGC.
Methods
We reviewed 58 patients with AGC treated with nivolumab from October 2017 to November 2018 at five participating institutions. We performed blood tests before the start of nivolumab and after administration of two courses. We evaluated the correlation between the best overall response and GRIm-s. Additionally, we focused on the changes in GRIm-s before the start of nivolumab and after administration of two courses.
Results
Of the 58 patients, 21 (36.2%) were classified into the disease control (DC) group and 37 (63.8%) into the progressive disease (PD) group. GRIm-s before nivolumab treatment did not correlate with the best therapeutic response (
p
= 0.086). However, GRIm-s after two courses of nivolumab showed that significantly more PD cases were in the high-risk group (
p
< 0.0001). After two courses of nivolumab, overall survival was significantly worse in the high-risk group (
p
< 0.0001). For progression-free survival, the high-risk group had a significantly worse prognosis both before (
p
= 0.04) and after two courses of nivolumab treatment (
p
< 0.0001).
Conclusions
GRIm-s after two courses of nivolumab and its changes compared to pretreatment values proved beneficial in predicting nivolumab sensitivity. |
| doi_str_mv | 10.1245/s10434-022-12226-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2692073593</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2692073593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-52144e745876daa98afb28d123b22557250fc3dd3176a69eb44ef6d7ea2367703</originalsourceid><addsrcrecordid>eNp9kctu1DAUhiMEUkvhBbqyxIYFKfbxLWE3GpWhUluqtqwtT3LSSUniwZdB82C8X50OElIXrHw53_-fY_9FccroGQMhPwdGBRclBSgZAKhSvCqOmcxXQlXsdd5TVZU1KHlUvA3hkVKmOZXHxZ_lxk4PGEg_kbhBskoh2h2SW5dC2JOLcUwTkrvGeSQ2EEtu3G_0XRrIjXcPkwuxb8iV9T_RE9c9W9xv0Nstprlyh1PoY7_r434uX_c7N6TRrud2i3ZnpwZbsrIh-gwv56P_QhbkKg1ZjVNE_4ncYvQubLHJPnmUmNr9u-JNZ4eA7_-uJ8WPr-f3y2_l5ffVxXJxWTaCVbGUwIRALWSlVWttXdluDVXLgK8BpNQgadfwtuVMK6tqXGe6U61GC1xpTflJ8fHgu_XuV8IQzdiHBofBTpg_yICqgWoua57RDy_QR5f8lKczoIFDBaIWmYID1eQnBY-d2fp-tH5vGDVzkuaQpMlJmuckzSziB1HIcA7L_7P-j-oJDaui1w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2723282494</pqid></control><display><type>article</type><title>Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study</title><source>SpringerLink Journals</source><creator>Nakazawa, Nobuhiro ; Sohda, Makoto ; Ubukata, Yasunari ; Kuriyama, Kengo ; Kimura, Akiharu ; Kogure, Norimichi ; Hosaka, Hisashi ; Naganuma, Atsushi ; Sekiguchi, Masanori ; Saito, Kana ; Ogata, Kyoichi ; Sano, Akihiko ; Sakai, Makoto ; Ogawa, Hiroomi ; Shirabe, Ken ; Saeki, Hiroshi</creator><creatorcontrib>Nakazawa, Nobuhiro ; Sohda, Makoto ; Ubukata, Yasunari ; Kuriyama, Kengo ; Kimura, Akiharu ; Kogure, Norimichi ; Hosaka, Hisashi ; Naganuma, Atsushi ; Sekiguchi, Masanori ; Saito, Kana ; Ogata, Kyoichi ; Sano, Akihiko ; Sakai, Makoto ; Ogawa, Hiroomi ; Shirabe, Ken ; Saeki, Hiroshi</creatorcontrib><description>Background
Identification of positive biomarkers for the effects of nivolumab on patients with advanced gastric cancer (AGC) is significant. The Gustave Roussy Immune Score (GRIm-s) is associated with therapeutic resistance of immune checkpoint inhibitors (ICIs) in other cancers. This multicenter, retrospective study was designed to analyze the association of GRIm-s with therapeutic sensitivity of nivolumab in patients with AGC.
Methods
We reviewed 58 patients with AGC treated with nivolumab from October 2017 to November 2018 at five participating institutions. We performed blood tests before the start of nivolumab and after administration of two courses. We evaluated the correlation between the best overall response and GRIm-s. Additionally, we focused on the changes in GRIm-s before the start of nivolumab and after administration of two courses.
Results
Of the 58 patients, 21 (36.2%) were classified into the disease control (DC) group and 37 (63.8%) into the progressive disease (PD) group. GRIm-s before nivolumab treatment did not correlate with the best therapeutic response (
p
= 0.086). However, GRIm-s after two courses of nivolumab showed that significantly more PD cases were in the high-risk group (
p
< 0.0001). After two courses of nivolumab, overall survival was significantly worse in the high-risk group (
p
< 0.0001). For progression-free survival, the high-risk group had a significantly worse prognosis both before (
p
= 0.04) and after two courses of nivolumab treatment (
p
< 0.0001).
Conclusions
GRIm-s after two courses of nivolumab and its changes compared to pretreatment values proved beneficial in predicting nivolumab sensitivity.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-022-12226-4</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Disease control ; Gastric cancer ; Immune checkpoint inhibitors ; Immunotherapy ; Medical prognosis ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; Oncology ; Patients ; Risk groups ; Surgery ; Surgical Oncology ; Targeted cancer therapy ; Translational Research</subject><ispartof>Annals of surgical oncology, 2022-11, Vol.29 (12), p.7400-7406</ispartof><rights>Society of Surgical Oncology 2022</rights><rights>Society of Surgical Oncology 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-52144e745876daa98afb28d123b22557250fc3dd3176a69eb44ef6d7ea2367703</citedby><cites>FETCH-LOGICAL-c418t-52144e745876daa98afb28d123b22557250fc3dd3176a69eb44ef6d7ea2367703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-022-12226-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-022-12226-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids></links><search><creatorcontrib>Nakazawa, Nobuhiro</creatorcontrib><creatorcontrib>Sohda, Makoto</creatorcontrib><creatorcontrib>Ubukata, Yasunari</creatorcontrib><creatorcontrib>Kuriyama, Kengo</creatorcontrib><creatorcontrib>Kimura, Akiharu</creatorcontrib><creatorcontrib>Kogure, Norimichi</creatorcontrib><creatorcontrib>Hosaka, Hisashi</creatorcontrib><creatorcontrib>Naganuma, Atsushi</creatorcontrib><creatorcontrib>Sekiguchi, Masanori</creatorcontrib><creatorcontrib>Saito, Kana</creatorcontrib><creatorcontrib>Ogata, Kyoichi</creatorcontrib><creatorcontrib>Sano, Akihiko</creatorcontrib><creatorcontrib>Sakai, Makoto</creatorcontrib><creatorcontrib>Ogawa, Hiroomi</creatorcontrib><creatorcontrib>Shirabe, Ken</creatorcontrib><creatorcontrib>Saeki, Hiroshi</creatorcontrib><title>Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><description>Background
Identification of positive biomarkers for the effects of nivolumab on patients with advanced gastric cancer (AGC) is significant. The Gustave Roussy Immune Score (GRIm-s) is associated with therapeutic resistance of immune checkpoint inhibitors (ICIs) in other cancers. This multicenter, retrospective study was designed to analyze the association of GRIm-s with therapeutic sensitivity of nivolumab in patients with AGC.
Methods
We reviewed 58 patients with AGC treated with nivolumab from October 2017 to November 2018 at five participating institutions. We performed blood tests before the start of nivolumab and after administration of two courses. We evaluated the correlation between the best overall response and GRIm-s. Additionally, we focused on the changes in GRIm-s before the start of nivolumab and after administration of two courses.
Results
Of the 58 patients, 21 (36.2%) were classified into the disease control (DC) group and 37 (63.8%) into the progressive disease (PD) group. GRIm-s before nivolumab treatment did not correlate with the best therapeutic response (
p
= 0.086). However, GRIm-s after two courses of nivolumab showed that significantly more PD cases were in the high-risk group (
p
< 0.0001). After two courses of nivolumab, overall survival was significantly worse in the high-risk group (
p
< 0.0001). For progression-free survival, the high-risk group had a significantly worse prognosis both before (
p
= 0.04) and after two courses of nivolumab treatment (
p
< 0.0001).
Conclusions
GRIm-s after two courses of nivolumab and its changes compared to pretreatment values proved beneficial in predicting nivolumab sensitivity.</description><subject>Disease control</subject><subject>Gastric cancer</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunotherapy</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>Oncology</subject><subject>Patients</subject><subject>Risk groups</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Targeted cancer therapy</subject><subject>Translational Research</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kctu1DAUhiMEUkvhBbqyxIYFKfbxLWE3GpWhUluqtqwtT3LSSUniwZdB82C8X50OElIXrHw53_-fY_9FccroGQMhPwdGBRclBSgZAKhSvCqOmcxXQlXsdd5TVZU1KHlUvA3hkVKmOZXHxZ_lxk4PGEg_kbhBskoh2h2SW5dC2JOLcUwTkrvGeSQ2EEtu3G_0XRrIjXcPkwuxb8iV9T_RE9c9W9xv0Nstprlyh1PoY7_r434uX_c7N6TRrud2i3ZnpwZbsrIh-gwv56P_QhbkKg1ZjVNE_4ncYvQubLHJPnmUmNr9u-JNZ4eA7_-uJ8WPr-f3y2_l5ffVxXJxWTaCVbGUwIRALWSlVWttXdluDVXLgK8BpNQgadfwtuVMK6tqXGe6U61GC1xpTflJ8fHgu_XuV8IQzdiHBofBTpg_yICqgWoua57RDy_QR5f8lKczoIFDBaIWmYID1eQnBY-d2fp-tH5vGDVzkuaQpMlJmuckzSziB1HIcA7L_7P-j-oJDaui1w</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Nakazawa, Nobuhiro</creator><creator>Sohda, Makoto</creator><creator>Ubukata, Yasunari</creator><creator>Kuriyama, Kengo</creator><creator>Kimura, Akiharu</creator><creator>Kogure, Norimichi</creator><creator>Hosaka, Hisashi</creator><creator>Naganuma, Atsushi</creator><creator>Sekiguchi, Masanori</creator><creator>Saito, Kana</creator><creator>Ogata, Kyoichi</creator><creator>Sano, Akihiko</creator><creator>Sakai, Makoto</creator><creator>Ogawa, Hiroomi</creator><creator>Shirabe, Ken</creator><creator>Saeki, Hiroshi</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20221101</creationdate><title>Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study</title><author>Nakazawa, Nobuhiro ; Sohda, Makoto ; Ubukata, Yasunari ; Kuriyama, Kengo ; Kimura, Akiharu ; Kogure, Norimichi ; Hosaka, Hisashi ; Naganuma, Atsushi ; Sekiguchi, Masanori ; Saito, Kana ; Ogata, Kyoichi ; Sano, Akihiko ; Sakai, Makoto ; Ogawa, Hiroomi ; Shirabe, Ken ; Saeki, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-52144e745876daa98afb28d123b22557250fc3dd3176a69eb44ef6d7ea2367703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Disease control</topic><topic>Gastric cancer</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunotherapy</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>Oncology</topic><topic>Patients</topic><topic>Risk groups</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Targeted cancer therapy</topic><topic>Translational Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakazawa, Nobuhiro</creatorcontrib><creatorcontrib>Sohda, Makoto</creatorcontrib><creatorcontrib>Ubukata, Yasunari</creatorcontrib><creatorcontrib>Kuriyama, Kengo</creatorcontrib><creatorcontrib>Kimura, Akiharu</creatorcontrib><creatorcontrib>Kogure, Norimichi</creatorcontrib><creatorcontrib>Hosaka, Hisashi</creatorcontrib><creatorcontrib>Naganuma, Atsushi</creatorcontrib><creatorcontrib>Sekiguchi, Masanori</creatorcontrib><creatorcontrib>Saito, Kana</creatorcontrib><creatorcontrib>Ogata, Kyoichi</creatorcontrib><creatorcontrib>Sano, Akihiko</creatorcontrib><creatorcontrib>Sakai, Makoto</creatorcontrib><creatorcontrib>Ogawa, Hiroomi</creatorcontrib><creatorcontrib>Shirabe, Ken</creatorcontrib><creatorcontrib>Saeki, Hiroshi</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakazawa, Nobuhiro</au><au>Sohda, Makoto</au><au>Ubukata, Yasunari</au><au>Kuriyama, Kengo</au><au>Kimura, Akiharu</au><au>Kogure, Norimichi</au><au>Hosaka, Hisashi</au><au>Naganuma, Atsushi</au><au>Sekiguchi, Masanori</au><au>Saito, Kana</au><au>Ogata, Kyoichi</au><au>Sano, Akihiko</au><au>Sakai, Makoto</au><au>Ogawa, Hiroomi</au><au>Shirabe, Ken</au><au>Saeki, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><date>2022-11-01</date><risdate>2022</risdate><volume>29</volume><issue>12</issue><spage>7400</spage><epage>7406</epage><pages>7400-7406</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background
Identification of positive biomarkers for the effects of nivolumab on patients with advanced gastric cancer (AGC) is significant. The Gustave Roussy Immune Score (GRIm-s) is associated with therapeutic resistance of immune checkpoint inhibitors (ICIs) in other cancers. This multicenter, retrospective study was designed to analyze the association of GRIm-s with therapeutic sensitivity of nivolumab in patients with AGC.
Methods
We reviewed 58 patients with AGC treated with nivolumab from October 2017 to November 2018 at five participating institutions. We performed blood tests before the start of nivolumab and after administration of two courses. We evaluated the correlation between the best overall response and GRIm-s. Additionally, we focused on the changes in GRIm-s before the start of nivolumab and after administration of two courses.
Results
Of the 58 patients, 21 (36.2%) were classified into the disease control (DC) group and 37 (63.8%) into the progressive disease (PD) group. GRIm-s before nivolumab treatment did not correlate with the best therapeutic response (
p
= 0.086). However, GRIm-s after two courses of nivolumab showed that significantly more PD cases were in the high-risk group (
p
< 0.0001). After two courses of nivolumab, overall survival was significantly worse in the high-risk group (
p
< 0.0001). For progression-free survival, the high-risk group had a significantly worse prognosis both before (
p
= 0.04) and after two courses of nivolumab treatment (
p
< 0.0001).
Conclusions
GRIm-s after two courses of nivolumab and its changes compared to pretreatment values proved beneficial in predicting nivolumab sensitivity.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.1245/s10434-022-12226-4</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2022-11, Vol.29 (12), p.7400-7406 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2692073593 |
| source | SpringerLink Journals |
| subjects | Disease control Gastric cancer Immune checkpoint inhibitors Immunotherapy Medical prognosis Medicine Medicine & Public Health Monoclonal antibodies Oncology Patients Risk groups Surgery Surgical Oncology Targeted cancer therapy Translational Research |
| title | Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T03%3A41%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20the%20Gustave%20Roussy%20Immune%20Score%20as%20a%20Powerful%20Prognostic%20Marker%20of%20the%20Therapeutic%20Sensitivity%20of%20Nivolumab%20in%20Advanced%20Gastric%20Cancer:%20A%20Multicenter,%20Retrospective%20Study&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Nakazawa,%20Nobuhiro&rft.date=2022-11-01&rft.volume=29&rft.issue=12&rft.spage=7400&rft.epage=7406&rft.pages=7400-7406&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-022-12226-4&rft_dat=%3Cproquest_cross%3E2692073593%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2723282494&rft_id=info:pmid/&rfr_iscdi=true |